CN111278855B - 新的t细胞受体 - Google Patents

新的t细胞受体 Download PDF

Info

Publication number
CN111278855B
CN111278855B CN201880069546.9A CN201880069546A CN111278855B CN 111278855 B CN111278855 B CN 111278855B CN 201880069546 A CN201880069546 A CN 201880069546A CN 111278855 B CN111278855 B CN 111278855B
Authority
CN
China
Prior art keywords
tcr
cells
cancer
cell
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880069546.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111278855A (zh
Inventor
A·苏厄尔
G·多尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CN111278855A publication Critical patent/CN111278855A/zh
Application granted granted Critical
Publication of CN111278855B publication Critical patent/CN111278855B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880069546.9A 2017-10-26 2018-10-22 新的t细胞受体 Expired - Fee Related CN111278855B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1717578.7 2017-10-26
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
GB1806155.6 2018-04-16
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (2)

Publication Number Publication Date
CN111278855A CN111278855A (zh) 2020-06-12
CN111278855B true CN111278855B (zh) 2024-04-02

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880069546.9A Expired - Fee Related CN111278855B (zh) 2017-10-26 2018-10-22 新的t细胞受体

Country Status (17)

Country Link
US (2) US11725039B2 (https=)
EP (2) EP3700925B8 (https=)
JP (1) JP7289311B2 (https=)
KR (1) KR20200078497A (https=)
CN (1) CN111278855B (https=)
AU (2) AU2018356944A1 (https=)
BR (1) BR112020007880A2 (https=)
CA (1) CA3077635A1 (https=)
DK (1) DK3700925T3 (https=)
EA (1) EA202091015A1 (https=)
ES (1) ES2907819T3 (https=)
GB (2) GB201717578D0 (https=)
IL (1) IL274025A (https=)
MX (1) MX2020004334A (https=)
PL (1) PL3700925T3 (https=)
SG (1) SG11202002537WA (https=)
WO (1) WO2019081902A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
AU2021208955A1 (en) * 2020-01-16 2022-07-21 Universität Basel MR1 ligands and pharmaceutical compositions for immunomodulation
US20240016837A1 (en) * 2020-06-10 2024-01-18 Eutilex Co., Ltd. T-cell receptor binding to mr1, and use thereof
JP2023549098A (ja) * 2020-11-04 2023-11-22 フェイト セラピューティクス，インコーポレイティド 固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
JPWO2022244876A1 (https=) * 2021-05-20 2022-11-24
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377290A (zh) * 2013-08-05 2016-03-02 伊玛提克斯生物技术有限公司 用于治疗多种肿瘤(例如包括nsclc在内的肺癌)的新型免疫疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
WO2018162563A1 (en) * 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377290A (zh) * 2013-08-05 2016-03-02 伊玛提克斯生物技术有限公司 用于治疗多种肿瘤(例如包括nsclc在内的肺癌)的新型免疫疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
clinical relevance of cirulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer;EJ Won,et al.;《Oncotarget》;第7卷(第46期);第76274-76290页 *

Also Published As

Publication number Publication date
EP3700925A1 (en) 2020-09-02
AU2018356944A1 (en) 2020-04-16
US11725039B2 (en) 2023-08-15
US20210147506A1 (en) 2021-05-20
EP3700925B1 (en) 2021-12-29
KR20200078497A (ko) 2020-07-01
JP2021500406A (ja) 2021-01-07
EA202091015A1 (ru) 2020-07-17
CN111278855A (zh) 2020-06-12
WO2019081902A1 (en) 2019-05-02
GB201717578D0 (en) 2017-12-13
CA3077635A1 (en) 2019-05-02
JP7289311B2 (ja) 2023-06-09
DK3700925T3 (en) 2022-04-04
MX2020004334A (es) 2020-08-03
GB201806155D0 (en) 2018-05-30
EP3700925B8 (en) 2022-02-16
US20200369742A1 (en) 2020-11-26
PL3700925T3 (pl) 2022-05-02
BR112020007880A2 (pt) 2020-10-27
IL274025A (en) 2020-06-30
ES2907819T3 (es) 2022-04-26
EP4039700A1 (en) 2022-08-10
AU2024202735A1 (en) 2024-05-30
SG11202002537WA (en) 2020-05-28
US11078252B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
CN111278855B (zh) 新的t细胞受体
US11945854B2 (en) Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
TWI764886B (zh) 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
US10537624B2 (en) Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
US11730796B2 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN109803983A (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞，其制备方法和应用
CN113195527A (zh) Tcr和肽
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
CN111372944A (zh) 新型γδT细胞受体和其配体
AU2022377062A1 (en) T cell receptor recognizing r175h mutation in p53 and its application
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
HK40034405A (en) Novel t-cell receptor
HK40034405B (en) Novel t-cell receptor
EA045252B1 (ru) Новый т-клеточный рецептор
HK40099489A (zh) 用於癌症免疫治疗的转染t细胞和t细胞受体
EP4472742A1 (en) Novel t-cell receptor
WO2023077102A1 (en) T cell receptor recognizing s37f mutation in ctnnb1 and its application
HK40058915A (en) Tcr and peptides
BR122024024508A2 (pt) Construto reconhecedor de antígeno, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método de fabricação de uma linhagem celular que expressa um construto reconhecedor de antígeno aat específico

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240402

CF01 Termination of patent right due to non-payment of annual fee